image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

Vesicle <i>p</i>H fluctuations are constant over a range of <i>p</i>H values. by Apeksha Singh (8174256)

Forest plot of included studies for the pooled WMD estimate of MPV between PE and NT groups using a random effect model. by Muluken Walle (13794209)

Decrease in the mean age at onset of T2DM across different BMI categories in hypertensive and non-hypertensive patients. by Arshad Mohamed Channanath (553879)

Mean and standard deviation of the three dimensions and of the global score of STS before COVID-19. by Martina Gnerre (12329356)

Mean and standard deviation of the three dimensions and of the global score of STS during COVID-19. by Martina Gnerre (12329356)

Mean and standard deviation of the three dimensions and of the global score of STS after COVID-19. by Martina Gnerre (12329356)

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Salience of authority-virtue phrases by year. by Daniel Hart (440152)

Decreased neutrophil and monocyte antigen expression in the paws of anti-S100A9-treated mice. by Annabelle Cesaro (112070)

Mean projected epidemic trajectories from simulated one- and two-dose reactive vaccination campaigns compared to observed epidemics. by Andrew S. Azman (121645)

Example of a raw sEMG signal of the gastrocnemius muscle. by I. Moll (14227650)

Clearance of PAG concentrations in postpartum beef cattle (A) and overall comparison between parity (B). by Adalaide C. Kline (19226172)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”